BioNexus Gene Lab Corp financial data

Symbol
BGLC on Nasdaq
Industry
Services-Medical Laboratories
Location
10 2 Tower B, Vertical Business Suite,, 8 Jalan Kerinchi,, Kuala Lumpur, Malaysia
State of incorporation
WY
Fiscal year end
December 31
Former names
BioNexus Gene Lab Coporation (to 5/8/2020)
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 466 % +15.9%
Quick Ratio 75.4 % +17.4%
Debt-to-equity 19.5 % -15.5%
Return On Equity -17.5 % +48.9%
Return On Assets -14.6 % +45.9%
Operating Margin -16.6 % +37.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18M shares +1.7%
Common Stock, Shares, Outstanding 18M shares +1.7%
Entity Public Float 8.16M USD -87.7%
Common Stock, Value, Issued 17.3M USD +0.82%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.51M USD -2.66%
Cost of Revenue 8.22M USD -2.61%
General and Administrative Expense 1.97M USD -19.2%
Operating Income (Loss) -1.57M USD +39.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.59M USD +38.8%
Income Tax Expense (Benefit) -3.49K USD +83.8%
Net Income (Loss) Attributable to Parent -1.6M USD +39.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Inventory, Net 1.39M USD +22%
Assets, Current 7.43M USD -7.66%
Property, Plant and Equipment, Net 1.52M USD +0.75%
Operating Lease, Right-of-Use Asset 215K USD +52.1%
Assets 10.4M USD -8.47%
Accounts Payable, Current 1.5M USD +7.21%
Liabilities, Current 1.95M USD +19.6%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 160K USD +61.7%
Liabilities 2.11M USD +21.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -555K USD +18.1%
Retained Earnings (Accumulated Deficit) -3.44M USD -86.7%
Stockholders' Equity Attributable to Parent 8.32M USD -13.8%
Liabilities and Equity 10.4M USD -8.47%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.4K USD +70.4%
Net Cash Provided by (Used in) Financing Activities 24.2K USD
Net Cash Provided by (Used in) Investing Activities 24.1K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 18M shares +1.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -97.2K USD +33.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.89M USD -36.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.66K USD +90.6%
Operating Lease, Liability 211K USD +57.8%
Depreciation 20.1K USD -3.63%
Payments to Acquire Property, Plant, and Equipment 102 USD -99.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.48M USD +49.1%
Property, Plant and Equipment, Gross 2.51M USD +4.57%
Operating Lease, Liability, Current 50.8K USD +46.7%
Deferred Income Tax Expense (Benefit) 16K USD +886%
Preferred Stock, Shares Authorized 30M shares 0%
Additional Paid in Capital -5.01M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 62.9K USD +71.8%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 0 USD -100%
Operating Leases, Future Minimum Payments, Due in Three Years 62.3K USD +70.1%
Operating Leases, Future Minimum Payments Due 239K USD +53.6%
Interest Expense 6.19K USD +45.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares